ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2006
Somatic stem cells and the origin of cancer.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- The most likely but largely ignored triggering factor for breast (or all) cancer invasion.Journal of Cancer · 2023Article
- Single-cell genomic profile-based analysis of tissue differentiation in colorectal cancer.Science China. Life sciences · 2021Article
- Regenerative medicine and injection therapies in stress urinary incontinence.Nature reviews. Urology · 2020Review
- Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs.BioMed research international · 2017Review
- Lung cancer stem cells-characteristics, phenotype.Translational lung cancer research · 2016Review
- Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal.Frontiers in oncology · 2016Review
- Competing views on cancer.Journal of biosciences · 2014Article
- Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III.Cancer research · 2014Article
- Cancer stem cells: progress and challenges in lung cancer.Stem cell investigation · 2014Review
- The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies.The oncologist · 2012Review
- Mesenchymal stem cell-derived hepatocytes for functional liver replacement.Frontiers in immunology · 2012Article
- Down-regulation of miR-302b, an ESC-specific microRNA, in Gastric Adenocarcinoma.Cell journal · 2012Article
- Molecular marks for epigenetic identification of developmental and cancer stem cells.Clinical epigenetics · 2011Article
- Anti-human embryonic stem cell monoclonal antibody Hesca-2 binds to a glycan epitope commonly found on carcinomas.Stem cells and development · 2011Article
- A stem cell niche dominance theorem.BMC systems biology · 2011Article
- A resource for discovering specific and universal biomarkers for distributed stem cells.PloS one · 2011Article
- Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer.ISRN oncology · 2011Article
- Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder.Seminars in reproductive medicine · 2010Review
- miR-145-mediated suppression of cell growth, invasion and metastasis.American journal of translational research · 2010Article
- Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype.Journal of ovarian research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most human cancers derive from a single cell targeted by genetic and epigenetic alterations that initiate malignant transformation. Progressively, these early cancer cells give rise to different generations of daughter cells that accumulate additional mutations, acting in concert to drive the full neoplastic phenotype. As we have currently deciphered many of the gene pathways disrupted in cancer, our knowledge about the nature of the normal cells susceptible to transformation upon mutation has remained more elusive. Adult stem cells are those that show long-term replicative potential, together with the capacities of self-renewal and multi-lineage differentiation. These stem cell properties are tightly regulated in normal development, yet their alteration may be a critical issue for tumorigenesis. This concept has arisen from the striking degree of similarity noted between somatic stem cells and cancer cells, including the fundamental abilities to self-renew and differentiate. Given these shared attributes, it has been proposed that cancers are caused by transforming mutations occurring in tissue-specific stem cells. This hypothesis has been functionally supported by the observation that among all cancer cells within a particular tumor, only a minute cell fraction has the exclusive potential to regenerate the entire tumor cell population; these cells with stem-like properties have been termed cancer stem cells. Cancer stem cells can originate from mutation in normal somatic stem cells that deregulate their physiological programs. Alternatively, mutations may target more committed progenitor cells or even mature cells, which become reprogrammed to acquire stem-like functions. In any case, mutated genes should promote expansion of stem/progenitor cells, thus increasing their predisposition to cancer development by expanding self-renewal and pluripotency over their normal tendency towards relative quiescency and proper differentiation.
Indexed as
Identifiers
17005467What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.